Skip to main content

Pembrolizumab + Single-Agent Chemotherapy

Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

  • RegistryNCT04297605
  • PhasePhase 1
  • StatusRecruiting
  • ConditionLocally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2)
  • SponsorUniversity of Rochester
How Pembrolizumab + Single-Agent Chemotherapy worksNCT042976051 min

What the film says

Read the transcript

This trial is for locally advanced or metastatic non-small cell lung cancer, in adults whose daily activity is limited, called performance status 2.

The idea: pair immunotherapy with a single chemotherapy drug. Pembrolizumab is given with either pemetrexed or nab-paclitaxel, every 21 days, as first treatment. The study enrolls patients with stage three C or stage four disease.

This pilot phase 1 study asks whether the combination is tolerable, and plans 60 patients. At the University of Rochester in New York, Megan Baumgart leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04297605

    Locally advanced or metastatic NSCLC, adults with performance status 2; Pembrolizumab with pemetrexed or nab-paclitaxel, every 21 days, first treatment; Pilot phase 1; tolerable; 60 patients; University of Rochester, New York; Megan Baumgart (+1 more lines)

The drug

What is being tested.

500 mg/m2 day 1 of 21 day cycle (for non-squamous only)

100 mg/m2 days 1,8 of 21 day cycle x 4 cycles

The study

How the trial runs.

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Participants must be >18 years old at time of diagnosis
  • Histologically confirmed non-small cell lung cancer
  • Clinical staging of IIIc or IV disease.
  • 4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation.
  • 4B. For patients with stage IV disease, platinum doublet chemotherapy is not appropriate, deemed unsafe by the treating physician, or declined by the patient

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.